Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mirailab Bioscience Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This level of activity indicates a focused effort to secure patent rights for specialized biological innovations. The 2 pending actions represent the company's current front in the patent prosecution process.
The portfolio involves 2 distinct examiners and 2 distinct art units. This 1:1 ratio between actions and examiners means that each of the 2 pending matters is being reviewed by a different individual in a different administrative section. This distribution prevents any single examiner from having a dominant influence over the company's current Biotechnology & Pharmaceuticals portfolio.
ALLEY, GENEVIEVE S is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. Since this examiner only manages 1 of the 2 total actions, the workload is evenly distributed. To succeed, the company must address the specific requirements of 2 different examiners across 2 separate art units within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847268 | AGENT FOR ORAL DISEASES | ALLEY, GENEVIEVE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847268 | AGENT FOR ORAL DISEASES | ALLEY, GENEVIEVE S | — |
| 18689437 | HEART DISEASE AGENT AND METHOD FOR IMPROVING HEART DISEASE | LEE, HOI YAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847268 | AGENT FOR ORAL DISEASES | ALLEY, GENEVIEVE S | 1617 | §102§103§112 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18689437 | HEART DISEASE AGENT AND METHOD FOR IMPROVING HEART DISEASE | LEE, HOI YAN NMN | 1693 | §102§103§112DP | Non-Final OA | — | Pending | Mar 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMirailab Bioscience Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Genevieve S Alley has the most, with 1 of Mirailab Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
